Boltz
Series A · $110M
AI drug discovery startup that develops open-source and proprietary AI models to help pharmaceutical and biotech researchers design and evaluate drug candidates.
About Boltz
It has raised $110M in disclosed funding. FundFinder classes it as AI & ML.
Its investors also appear on FundFinder's most-active lists for Series A · Fintech (84 funds), Series A · B2B (81 funds), Series A · Generalist (63 funds).
Company facts from Harmonic and public filings; team backgrounds from public profiles. Refreshed weekly.
Want the latest on Boltz? Our research agent pulls the current
description, latest round and full investor base from public sources (about a minute).
Series A · $110M · Nov 2026
- Andreessen Horowitz — US based and global investors, Andreessen is a multi-stage investor with a number of portfolio services and a well known reputation in the industry
- Hummingbird Ventures — Hummingbird Ventures was founded in Antwerp and is now based in London. · cheques £500k – £10M

